

Pyrazinamide

FORM 500mg in 5ml oral suspension

(500mg tablets can be used if oral suspension is not available – see below for more information)

INDICATION Unsupervised treatment of tuberculosis (TB)

DOSE RANGE

AGE	DOSE	FREQUENCY	ROUTE
Birth to 6months	35mg/kg*	ONCE daily	Oral

*If using tablets doses should be rounded to nearest 125mg if appropriate.

CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS

- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)

FURTHER INFORMATION

- Give for 1st 2 months of TB treatment only
- Not to be used for chemoprophylaxis
- Parents should be counselled to seek medical advice immediately if infant shows any signs of liver disorder e.g. vomiting, malaise, fever or jaundice.

STORAGE Store oral suspension in the fridge

LICENSED STATUS Unlicensed special

LINKS [BNF for Children:](#) / [Electronic Medicines Compendium](#)

APPLICABLE POLICIES [West of Scotland Neonatal Guidelines:](#)

Consult local policy if applicable

Document Number:	001	Supersedes:	Nil
Prepared by:	Hazel Fisher	Checked by	WoS Neonatal Pharmacists
Date prepared	January 2017	Date updated	
Updated by		Review Date	January 2019

Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications. This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.